II期临床-话题@MedSci

#II期临床#

478篇内容 | 2614人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524667, encodeId=13cb152466e33, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著, objectType=article, longId=156635, objectId=3f5e156635a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f5e156635a8, replyNumber=0, likeNumber=74, createdTime=2018-12-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f5e156635a8, moduleTitle=Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f5e156635a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524666, encodeId=71371524666c6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=76, createdTime=2018-12-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524665, encodeId=9635152466546, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156414, objectId=bb9a156414cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9a156414cc, replyNumber=0, likeNumber=0, createdTime=2018-12-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9a156414cc, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9a156414cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524664, encodeId=6dc81524664af, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156388, objectId=8ee71563888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee71563888f, replyNumber=0, likeNumber=82, createdTime=2018-12-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee71563888f, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee71563888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524663, encodeId=11991524663b0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, objectType=article, longId=154956, objectId=189915495643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=189915495643, replyNumber=0, likeNumber=51, createdTime=2018-12-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=189915495643, moduleTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=189915495643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524662, encodeId=3cbe1524662da, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ALK阳性肺癌全新III期临床研究成果, objectType=article, longId=154858, objectId=84b91548588d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b91548588d, replyNumber=0, likeNumber=60, createdTime=2018-12-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b91548588d, moduleTitle=ALK阳性肺癌全新III期临床研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b91548588d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524661, encodeId=6873152466129, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床, objectType=article, longId=153201, objectId=ee2f15320164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2f15320164, replyNumber=0, likeNumber=0, createdTime=2018-11-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2f15320164, moduleTitle=JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee2f15320164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524660, encodeId=ca3e152466086, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=87, createdTime=2018-10-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524659, encodeId=d5281524659e3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=20, createdTime=2018-09-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524658, encodeId=5ab6152465895, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, objectType=article, longId=149146, objectId=06fb149146c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fb149146c6, replyNumber=0, likeNumber=55, createdTime=2018-09-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fb149146c6, moduleTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fb149146c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524657, encodeId=496f152465e49, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表, objectType=article, longId=147648, objectId=0b0214e648e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b0214e648e1, replyNumber=0, likeNumber=69, createdTime=2018-08-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b0214e648e1, moduleTitle=Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b0214e648e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524656, encodeId=af9d1524656be, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, objectType=article, longId=146747, objectId=d9eb146e4766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9eb146e4766, replyNumber=0, likeNumber=65, createdTime=2018-08-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9eb146e4766, moduleTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9eb146e4766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524655, encodeId=5ae6152465574, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, objectType=article, longId=146735, objectId=31ee146e35d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ee146e35d9, replyNumber=0, likeNumber=93, createdTime=2018-08-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ee146e35d9, moduleTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ee146e35d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524654, encodeId=af5615246543a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动, objectType=article, longId=145966, objectId=6cc314596637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc314596637, replyNumber=0, likeNumber=46, createdTime=2018-08-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc314596637, moduleTitle=III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc314596637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524653, encodeId=b4da152465328, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组, objectType=article, longId=145963, objectId=4cb0145963c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cb0145963c1, replyNumber=0, likeNumber=49, createdTime=2018-08-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cb0145963c1, moduleTitle=II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cb0145963c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524652, encodeId=08fe15246522e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gastroenterology：GS-0976治疗非酒精性脂肪性肝炎II期临床效果显著, objectType=article, longId=145489, objectId=b5d414548996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5d414548996, replyNumber=0, likeNumber=26, createdTime=2018-07-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5d414548996, moduleTitle=Gastroenterology：GS-0976治疗非酒精性脂肪性肝炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5d414548996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524651, encodeId=7f1c152465174, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=103, createdTime=2018-07-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524650, encodeId=e9bf152465070, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=105, createdTime=2018-06-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524649, encodeId=008515246495f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=曲马多治疗术后疼痛的III期临床数据, objectType=article, longId=138881, objectId=706b138881e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=706b138881e9, replyNumber=0, likeNumber=86, createdTime=2018-05-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=706b138881e9, moduleTitle=曲马多治疗术后疼痛的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=706b138881e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524648, encodeId=8c8a1524648f9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=58, createdTime=2018-04-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：Pegbelfermin治疗非酒精性脂肪肝II期临床效果显著

2018-12-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2018-12-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2018-12-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2018-12-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗

2018-12-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ALK阳性肺癌全新III期临床研究成果

2018-12-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床

2018-11-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2018-10-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2018-09-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景

2018-09-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Thyroid：安罗替尼治疗甲状腺髓样癌II期临床研究结果在国际权威杂志发表

2018-08-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功

2018-08-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据

2018-08-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动

2018-08-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组

2018-08-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gastroenterology：GS-0976治疗非酒精性脂肪性肝炎II期临床效果显著

2018-07-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2018-07-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-06-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

曲马多治疗术后疼痛的III期临床数据

2018-05-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Vertex在III期临床试验中测试CF三联疗法

2018-04-30

科室
- - 订阅+
  - 更多科室
工具
服务